Otsuka's Head of U.S. GPV Safety Data Management Vikalp Khare shares how smart governance should inform pharmacovigilance (PV) technology choices.
- Safe And Sustainable DCTs and Hybrid Trials (Part 2)
- Forget More Clinical Tech, We Need More Adoption
- Joe Dustin: Sites Are Driving Clinical Tech Evolution
- How Salk And Sabin Helped Create The Modern Clinical Trial
- How To Operationalize AI-Enabled eTMF Systems Under The EU AI Act (Part 2)
- How AI-Enabled eTMF Systems Are Impacted By The EU AI Act (Part 1)
- Making AI Safety Routine: How Sites And Sponsors Can Continuously Monitor Clinical AI
- How Can AI Change Computerized System Validation?
ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS
-
Could ePRO Be The New Standard In Health Reimbursement?
Recently, early-phase protocols have been collecting patient-reported outcomes (PROs) not only to get regulatory approval but to demonstrate value to public and private payers.
-
eCOA/ePRO: Why Patients Deserve Even More Progress
The shift from reporting on paper to reporting electronically has been happening for years, however, the transition hasn’t always been elegant. Explore how the pandemic has played a role in accelerating the shift to eCOA/ePRO.
-
Empowering Freenome: Large-Scale Data Quality And Compliance
Delve into five ways this biotech company was able to successfully deliver data quality and compliance for large-scale trials while developing next-generation blood tests for early cancer detection.
-
Essity Uses eConsent To Optimize Enrollment
See how a global hygiene and health company was able to deploy virtual methods through a strategic partnership to recruit and retain participants, streamline consent, and analyze patient data.
-
Sustainable Clinical Trials Through eClinical Innovation
Clinical trials are essential to advancing medicine, yet they carry significant environmental costs. Inefficiencies not only drive emissions but also risk drug shortages and trial delays, and clinical technology solutions offer a pathway to more sustainable research.
-
Leveraging eCOA To Improve Patient Adherence In Clinical Trials
Patient adherence is one of the biggest challenges in clinical trials. eCOA solutions offer intuitive and engaging tools that encourage participants to complete their assessments on time.
-
Implementing Cognizant® Shared Investigator Platform: Lessons From The Field
One leading oncology healthcare system and research institution has recently successfully implemented Cognizant SIP and shares its best practices around planning for and implementing Cognizant SIP given such a large footprint.
-
OpenClinica EDC: Friendly & Easy to Deploy?
Find out how OpenClinica stands out in the global EDC landscape through its user-friendly interface, strong integration capabilities, and extensive partnerships.
-
6 Ways Lab Data Can Improve Clinical Trials
Explore six key ways laboratory data strengthens the clinical trial process, focusing on how RWD enhances patient recruitment, accelerates screening workflows, and improves overall study outcomes.
-
Navigating eCOA Licensing And Localization In Clinical Trials
eCOA has been key in trials for 20 years, but issues like licensing, localization, and execution quality still challenge sponsors.
FROM THE EDITOR
- Telehealth In Clinical Trials: What You Need To Know
- Forget More Clinical Tech, We Need More Adoption
- Joe Dustin: Sites Are Driving Clinical Tech Evolution
- How Salk And Sabin Helped Create The Modern Clinical Trial
- Why HEOR Keeps Arriving Too Late — And How ClinOps Can Fix It
- FDA Vs. MHRA Vs. EMA: Differences In Externally Controlled Trials
- RWE Is Growing Up, And Here's Why That Matters
FEATURED PRODUCTS & SERVICES
RECENT NEWSLETTERS
- 02.26.26 -- EU AI Act Compliance For eTMF Systems: What Clinical Tech Leaders Need To Know
- 02.19.26 -- The Clinical Tools Quietly Reshaping Trial Operations
- 02.12.26 -- How Can AI Change Computerized System Validation?
- 02.05.26 -- Digital Tools Are Failing Patients: Three Ways Clinical Supply Protects Data
- 01.29.26 -- Digital Protocols Are At An Inflection Point: A Conversation With Novartis And TransCelerate Leaders